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Main Text 
Beta-2 microglobulin (B2M) is the light chain in the major histocompatibility 
complex (MHC) Class 1 molecule [1], which is present in all nucleated cells. It has 
been suggested as an initiator of inflammation [2], and is an early marker of diseases 
related to inflammation such as cardiovascular  and renal disease [3, 4]. B2M is 
renally excreted and so the serum level increases in renal dysfunction. We and others 
have reported that serum B2M level predicts mortality in certain patient populations 
[3, 5-9]. We therefore examined whether serum B2M level predicted cardiovascular 
and all-cause mortality in a large nationally representative cohort.  
 
Data from the Third National Health and Nutrition Examination Survey (NHANES III) 
were used [10]. NHANES III was conducted by the National Center for Health 
Statistics from 1988 to 1994 using a stratified multistage probability sample which 
represented the civilian non-institutionalized U.S. population. Participants gave 
written consent before participation, and ethical approval was obtained from the 
Human Subjects Committee of the U.S. Department of Health and Human Services. 
Detailed study designs and measurements are provided in Supplementary Appendix.  
 
The median B2M level in study participants was 2.01 mg/L (IQR=1.66-2.55). 
Supplementary Table 1 shows their characteristics. During a median follow-up of 13.5 
years (range 0.1 to 18.2 years) and 79,528 person-years, 1,150 and 2,524 participants 
died from cardiovascular causes and all causes, respectively. Higher B2M levels were 
associated with cardiovascular and all-cause mortality. Kaplan-Meier survival curves 
showed that quartile 4 had a much higher mortality compared to the other quartiles 
(log-rank test <0.001; Figure 1a and 1b). Moreover, the survival curves diverged from 
the beginning and continued through 18.2 years. 
 
The results from Cox-regression analysis are shown in Supplementary Table 2. For 
all-cause mortality, a 1-unit increase of B2M was associated with HR of 1.89 (95% CI: 
1.79-2) for crude model, 1.38 (95% CI: 1.32-1.44) after adjustment for lifestyle 
factors, and 1.45 (95% CI: 1.35-1.56) after further adjustment for cardiometabolic risk 
factors. In multicategorical and threshold models, participants in highest quartile of 
B2M were at higher risk for all-cause mortality compared to quartile 1 and quartile 1 
through 3, respectively (Models 1-3, Supplementary Table 2). Examination of 
regression splines suggests an almost linear relationship between serum B2M and 
mortality risk (Figure 1c). Adjustment for additional renal function biomarkers 
(Supplementary Table 3) or excluding participants who died during first 2 years of 
follow-up (Supplementary Table 4) showed similar findings. The association of B2M 
level with all-cause mortality was consistent in selected subgroups (Figure 2). The HR 
was higher in those younger than 65 years of age and lower in those with less than 
high school education. 
 
For cardiovascular mortality, a 1-unit increase of B2M was associated with HR of 
1.93 (95% CI: 1.8-2.08) for the crude model, 1.4 (95% CI: 1.29-1.52) after adjustment 
for lifestyle factors, and 1.46 (95% CI: 1.31-1.64) after further adjustment for 
cardiometabolic risk factors. In multicategorical and threshold models, participants 
with the highest quartile of B2M were at higher risk of cardiovascular mortality 
compared with quartile 1 and quartile 1 through 3, respectively (Models 1-3, 
Supplementary Table 2). Examination of regression splines suggests an almost linear 
relationship between serum B2M and mortality (Figure 1d). Sensitivity analyses 
(Supplementary Tables 3 and 4) showed similar findings, except that the association 
became insignificant after further adjustment for additional renal function biomarkers 
in the multicategorical model. Association of B2M level with cardiovascular mortality 
was consistent in the subgroups examined, except in the subgroups of participants 
with education level lower than high school, diabetes, hypertension, and current 
smoker (Figure 2). 
 
Thus, the main finding of this study was that serum B2M concentration predicted 
cardiovascular and all-cause mortality in a large cohort representative of the American 
general population. This was independent of renal function, cancer, history of heart 
disease, and cardiometabolic and mortality risk factors.  
The association of B2M with mortality has been noted before [3, 5-9]. In our recent 
study, we showed that B2M is a predictor of mortality in diabetes patients [9]. As 
B2M reflects renal function, three studies examined its association of B2M with 
mortality in dialysis [6-7] or uremic [3] patients. These studies showed that B2M is a 
predictor of all-cause [3, 7] and infectious disease [6] mortality in people with renal 
impairment, although the association with cardiovascular mortality was inconsistent 
[3, 6]. In 1,034 individuals aged 65 or above, B2M was shown to be associated with 
all-cause mortality [8], with the middle (HR of 2.02 [95% CI: 1.35-3.04]) and upper 
(HR of 2.84 [95% CI: 1.92-4.20]) tertiles of B2M concentration being associated with 
higher mortality. Our study extends the finding to people younger than 65 years, in 
whom a single biomarker to identify at risk persons would be especially valuable. 
TheAtherosclerosis Risk in Communities (ARIC) Study examined several biomarkers 
of renal dysfunction (cystatin-C, BTP, and eGFR) and found that B2M had the 
strongest association with all-cause mortality in the general population [5]. In our 
analysis, we adjusted for renal function and showed that B2M was independently 
associated with cardiovascular and all-cause mortality (Supplementary Table 3).  
In conclusion, serum B2M concentration is associated with a significant increased risk 
of cardiovascular (up to 6-fold) and all-cause (up to 4-fold) mortality. The increased 
risk is immediate and extends to at least 18 years, and is especially pronounced in 
people under the age of 65. These tantalizing findings call for validation in another 
cohort and a formal and preferably prospective comparison with other biomarkers 
predicting mortality. [?Our preliminary comparison with the Framingham Risk Score 
(FRS) suggested that B2M is as good as, and adds to FRS in predicting cardiovascular 
and all-cause mortality. [cite our abstract]] If our findings are confirmed in other 
populations, we may have a novel and simple way of gauging prognosis and 
predicting mortality. 
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Figure 1. Kaplan-Meier cumulative survival curves for (a) all-cause and (b) 
cardiovascular mortality depending on quartiles of B2M; and association 
between serum beta-2 microglobulin and mortality assessed via penalized 
regression spline (c) all-cause and (d) cardiovascular mortality. 
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Figure 2. Adjusted hazard ratios for all-cause and cardiovascular mortality associated 
with beta-2 microglobulin above the median (>2.54 mg/L) in selected subgroups 
BMI: body mass index; eGFR: estimated glomerular filtration rate. 
 
 
 
 
